A Phase 1 interventional study of ONO-2020 and Placebo in Healthy Volunteers, sponsored by Ono Pharmaceutical Co. Ltd. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-09.
Sponsored by Ono Pharmaceutical Co. Ltd · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this FIH study is to evaluate the safety, tolerability and pharmacokinetics of ONO-2020 in healthy adult participants. This FIH study consists of five parts (Parts A-E) to study single or multiple doses of ONO-2020 in healthy participants, including elderly and Japanese participants, as well as the food effect on the PK of ONO-2020. These data will support the clinical development program and help inform dose selection in future studies.
Ono Pharmaceutical Co. Ltd is the lead sponsor of 63 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants who, in the opinion of the Investigator, are considered unsuitable for any other reason.
Exclusion criteria, applicable to all participants taking part in the food effect Cohort in Part A:
Participants who are vegetarian or vegan or not willing to eat a high-fat breakfast.
Exclusion criteria, applicable to all participants undergoing lumbar puncture for CSF collection (Part C):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single ascending doses of ONO-2020 orally under fasted conditions
Drug: ONO-2020 · Drug: Placebo
Single ascending doses of ONO-2020 orally under fasted and fed conditions
Drug: ONO-2020 · Drug: Placebo
Single ascending doses of ONO-2020 orally under fasted conditions
Drug: ONO-2020 · Drug: Placebo
Single ascending doses of ONO-2020 orally under fasted and fed conditions
Drug: ONO-2020 · Drug: Placebo
Single ascending doses of ONO-2020 orally under fasted conditions
Drug: ONO-2020 · Drug: Placebo
Single ascending doses of ONO-2020 orally under fasted conditions
Drug: ONO-2020 · Drug: Placebo
Multiple ascending doses of ONO-2020 orally for 14 days
Drug: ONO-2020 · Drug: Placebo
Multiple ascending doses of ONO-2020 orally for 14 days
Drug: ONO-2020 · Drug: Placebo
Multiple ascending doses of ONO-2020 orally for 14 days
Drug: ONO-2020 · Drug: Placebo
Multiple ascending doses of ONO-2020 orally for 14 days
Drug: ONO-2020 · Drug: Placebo
Multiple ascending doses of ONO-2020 orally for 14 days
Drug: ONO-2020 · Drug: Placebo
Single dose of ONO-2020 orally for CSF sampling
Drug: ONO-2020
Single dose of ONO-2020 orally for CSF sampling
Drug: ONO-2020
Single dose of ONO-2020 orally in elderly healthy volunteers
Drug: ONO-2020 · Drug: Placebo
Multiple ascending doses of ONO-2020 orally for 14 days in Japanese healthy volunteers
Drug: ONO-2020 · Drug: Placebo
Multiple ascending doses of ONO-2020 orally for 14 days in Japanese healthy volunteers
Drug: ONO-2020 · Drug: Placebo
ONO-2020 tablets
Placebo tablets matching ONO-2020 tablets
Incidence, severity, and type of treatment emergent adverse events (TEAEs)
Incidence of TEAEs will be summarized overall, and by study part and dose group using frequency and percentage.
Time frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21
Vital signs (blood pressure)
Observed values and change from baseline results will be summarized by analysis time point, and summaries of clinically significant and non-clinically significant abnormalities will be provided by each time point.
Time frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21
Vital signs (pulse rate)
Observed values and change from baseline results will be summarized by analysis time point, and summaries of clinically significant and non-clinically significant abnormalities will be provided by each time point.
Time frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21
Vital signs (body temperature)
Observed values and change from baseline results will be summarized by analysis time point, and summaries of clinically significant and non-clinically significant abnormalities will be provided by each time point.
Time frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21
Vital signs (respiratory rate)
Observed values and change from baseline results will be summarized by analysis time point, and summaries of clinically significant and non-clinically significant abnormalities will be provided by each time point.
Time frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21
12-lead electrocardiograms (ECGs) parameters, such as but not limited to heart rate, RR, PR, QRS, QT, and corrected QT intervals (QTcF)
The number and percentage of subjects with normal, abnormal not clinically significant and abnormal clinically significant of ECG results will be tabulated at each time point.
Time frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21
Clinically significant abnormal telemetry electrocardiograms (ECGs)
The number and percentage of subjects with normal, abnormal not clinically significant and abnormal clinically significant of telemetry ECGs results will be tabulated at each time point.
Time frame: Part A and D: Day 1
Clinically significant abnormal physical examination findings
The number and percentage of subjects with normal, abnormal not clinically significant and abnormal clinically significant of physical examination results will be tabulated at each time point.
Time frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21
Clinical laboratory abnormalities (hematology, clinical chemistry, coagulation, and urinalysis)
The number and percentage of subjects with abnormal laboratory results at any time during the study will be tabulated.
Time frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21
Ophthalmologic examination findings (pupil size and pupillary light reflex)
The number and percentage of subjects with miosis will be summarized by laterality at each time point.
Time frame: Part A, C and D: From Day 1 up to Day 7, Part B and E: From Day 1 up to Day 21
Clinically abnormal findings in Mini-International Neuropsychiatric Interview Screen (M.I.N.I.-Screen)
Responses to the M.I.N.I.-Screen will be listed.
Time frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21
Clinically abnormal findings in Columbia Suicide Severity Rating Scale (C-SSRS)
Responses to the suicidality assessment scale (C-SSRS) will be listed.
Time frame: Part A, C and D: From screening up to Day 7, Part B and E: From screening up to Day 21
Pharmacokinetics (Cmax in plasma)
Time frame: Part A, C and D: Day 1 through Day 4, Part B and E: Day 1 through Day 19
Pharmacokinetics (Tmax in plasma)
Time frame: Part A, C and D: Day 1 through Day 4, Part B and E: Day 1 through Day 19
Pharmacokinetics (AUClast in plasma)
Time frame: Part A, C and D: Day 1 through Day 4, Part B and E: Day 1 through Day 19
Pharmacokinetics (AUCinf in plasma)
Time frame: Part A, C and D: Day 1 through Day 4, Part B and E: Day 1 through Day 19
Pharmacokinetics (T1/2 in plasma)
Time frame: Part A, C and D: Day 1 through Day 4, Part B and E: Day 1 through Day 19
Pharmacokinetics (CL/F in plasma)
Time frame: Part A, C and D: Day 1 through Day 4, Part B and E: Day 1 through Day 19
Pharmacokinetics (Aet in urine)
Time frame: Part A and D: Day 1 through Day 4
Pharmacokinetics (fe/F in urine)
Time frame: Part A and D: Day 1 through Day 4
Pharmacokinetics (CLR in urine)
Time frame: Part A and D: Day 1 through Day 4
Pharmacokinetics (Ctrough in plasma)
Time frame: Part B and E: Day 2 through Day 13
Pharmacokinetics (ONO-2020 concentration in CSF)
Time frame: Part C: Day 2
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2022 to primary completion in Dec 2023, 16 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ONO-2020